ZA201505243B - Helicase-primase inhibitors for use in a method of treating alzheimer's disease - Google Patents

Helicase-primase inhibitors for use in a method of treating alzheimer's disease

Info

Publication number
ZA201505243B
ZA201505243B ZA2015/05243A ZA201505243A ZA201505243B ZA 201505243 B ZA201505243 B ZA 201505243B ZA 2015/05243 A ZA2015/05243 A ZA 2015/05243A ZA 201505243 A ZA201505243 A ZA 201505243A ZA 201505243 B ZA201505243 B ZA 201505243B
Authority
ZA
South Africa
Prior art keywords
helicase
disease
treating alzheimer
primase inhibitors
primase
Prior art date
Application number
ZA2015/05243A
Other languages
English (en)
Inventor
Ruth Itzhaki
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of ZA201505243B publication Critical patent/ZA201505243B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA2015/05243A 2013-02-12 2015-07-21 Helicase-primase inhibitors for use in a method of treating alzheimer's disease ZA201505243B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13154982 2013-02-12
PCT/EP2014/052743 WO2014124978A2 (en) 2013-02-12 2014-02-12 Helicase-primase inhibitors for use in a method of treating alzheimer's disease

Publications (1)

Publication Number Publication Date
ZA201505243B true ZA201505243B (en) 2017-11-29

Family

ID=47709982

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/05243A ZA201505243B (en) 2013-02-12 2015-07-21 Helicase-primase inhibitors for use in a method of treating alzheimer's disease

Country Status (16)

Country Link
US (1) US20150374676A1 (enExample)
EP (1) EP2956134A2 (enExample)
JP (1) JP2016507546A (enExample)
KR (1) KR20150119089A (enExample)
CN (1) CN105101963A (enExample)
AU (1) AU2014217962A1 (enExample)
BR (1) BR112015019220A2 (enExample)
CA (1) CA2898798A1 (enExample)
CL (1) CL2015002241A1 (enExample)
EA (1) EA201500836A1 (enExample)
IL (1) IL240459A0 (enExample)
MX (1) MX2015010339A (enExample)
PH (1) PH12015501762A1 (enExample)
SG (1) SG11201506153TA (enExample)
WO (1) WO2014124978A2 (enExample)
ZA (1) ZA201505243B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
ES2877854T3 (es) * 2016-11-28 2021-11-17 Aicuris Gmbh & Co Kg Una sal de maleato de la base libre de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, procedimientos de fabricación y usos de las mismas para el tratamiento de los virus del herpes
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
TW202038947A (zh) * 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
KR102456699B1 (ko) 2020-11-19 2022-10-19 주식회사 오에이티씨 디다노신을 포함하는 신경염증성 질환 예방 또는 치료용 조성물
EP4580601A1 (en) * 2022-08-29 2025-07-09 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
US8299059B2 (en) * 2009-10-30 2012-10-30 Eli Lilly And Company Crystalline compound and a process for its preparation
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range

Also Published As

Publication number Publication date
PH12015501762A1 (en) 2015-11-09
WO2014124978A3 (en) 2014-10-30
AU2014217962A1 (en) 2015-09-17
BR112015019220A2 (pt) 2017-07-18
CL2015002241A1 (es) 2016-02-19
WO2014124978A4 (en) 2014-12-24
CA2898798A1 (en) 2014-08-21
MX2015010339A (es) 2015-11-16
EA201500836A1 (ru) 2016-02-29
EP2956134A2 (en) 2015-12-23
JP2016507546A (ja) 2016-03-10
US20150374676A1 (en) 2015-12-31
SG11201506153TA (en) 2015-09-29
IL240459A0 (en) 2015-09-24
WO2014124978A2 (en) 2014-08-21
KR20150119089A (ko) 2015-10-23
CN105101963A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
IL266648B (en) A method for treating Parkinson's disease
IL278124B (en) Axl depressant pyridone derivative for use in the treatment of the disease
ZA201601024B (en) Methods and compositions for treating brain diseases
IL243976B (en) kdm1a inhibitors for disease treatment
PT2992908T (pt) Método para tratamento da superfície do implante
SG11201509729YA (en) Use of high dose pridopidine for treating huntington's disease
IL241347A0 (en) Methods for obtaining medically effective doses of anti-cd47 agents
HUE039560T2 (hu) Mikro méretû zárófedés és kapcsolódó eljárások bõr kezelésére
PT2948448T (pt) Análogos de tiadiazol e o seu uso para tratamento de doenças associadas a uma deficiência de neurónios motores smn
ZA201506534B (en) Method of treating hair
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
IL240812A0 (en) Unit and method for corona treatment
EP2941252A4 (en) USE OF FATTY ACID NIACIN CONJUGATES FOR THE TREATMENT OF DISEASES
SG11201506153TA (en) Helicase-primase inhibitors for use in a method of treating alzheimer's disease
AP2016009136A0 (en) A method for the treatment of metals
SG10201710538XA (en) Compositions and methods for treating skin
BR112014029487A2 (pt) método para o tratamento cosmético
PL3041831T3 (pl) Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
GB201308466D0 (en) Improved process for treatment of minewater
SMT202000175T1 (it) Oligonucleotide per tgf-beta modificato per l'uso in un metodo per prevenire e/o per trattare una malattia oftalmica
EP2892456A4 (en) PROCESS FOR PERMANENT REMOVAL OF HAIR
ZA201407215B (en) Method for emulsion treatment
GB201322174D0 (en) Process for treating steel components
PL3041506T3 (pl) Sposób leczenia
IL241482A0 (en) A method for treating Parkinson's disease